neoleukin analyst coverage

neoleukin analyst coverage

Progress Software (PRGS) initiated with a Neutral at Citi. Since then, NLTX shares have decreased by 34.5% and is now trading at $5.21. NLTX Competitors and Alternatives 2021 (Neoleukin ... We are applying our deep understanding of immunology and unparalleled expertise in polymer . The stock closed at $14.61 on Jan. 5. Analysts Have Conflicting Sentiments on These Healthcare ... Press Releases | Voyager Therapeutics Inc. Junior Analyst jobs 81,984 open jobs Client Manager jobs . Progress Software (PRGS) initiated with a Neutral at Citi. Neoleukin Therapeutics (NasdaqGM:NLTX) - Share price, News ... premium payments for continued healthcare coverage for up to nine months; and (iv) accelerated vesting of the portion of his then-outstanding equity awards that would have vested and become . Neoleukin Therapeutics is a smaller company with a market capitalization of US$319m, so it may still be flying under the radar of many institutional investors. Neoleukin Therapeutics, Inc. . The Investor Relations website contains information about Ovid Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. 5. Neoleukin Therapeutics (NLTX) assumed with an Overweight at Piper Sandler. Aquinox Pharmaceuticals, based in Vancouver, BC, and Neoleukin Therapeutics, a privately held biopharmaceutical company and University of Washington Spinout based in Seattle, WA, have agreed to enter into a definitive merger agreement under which Aquinox agreed to the acquisition of Neoleukin, which is expected to close on or about August 8th, 2019. Analyst Ranking. Neoleukin Therapeutics, Inc., "Neoleukin" (NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the . Save up to . The average price target for NLTX is $22.5 and analyst's rate the stock as a Strong Buy. Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Risk vs Reward. Karen L. Bergman. Advanced Charting. Neoleukin Therapeutics (NASDAQ:NLTX) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better business?We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. View which stocks have been most impacted by COVID-19. Neoleukin Therapeutics Inc NLTX . Fly Intel: Top five analyst initiations. The . The stock was acquired at an average cost of $6.11 per share, with a total value of $611,000.00. Report also provides prominent drugs for in-progress . IL-15 assets are included in this analysis as this cytokine is structurally similar to IL-2, and its beta and gamma chains are identical to IL-2's. At the Asco-GU congress in February Immunitybio presented promising data from the phase 2/3 Quilt-3.032 trial in non-muscle invasive bladder cancer in which Anktiva was given locally with BCG. Globalstar ( GSAT) - Get Globalstar, Inc. Report shares jumped on Monday after B. Riley began coverage of the mobile satellite services company with a buy rating and a price target of $3.25. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of . Neoleukin Therapeutics, Inc's price can fluctuate throughout the course of each trading day—when you buy Neoleukin Therapeutics, Inc through Stash, we execute the market order during our next available trading window (we have two a day). 4. Tyler Van Buren's Stock Forecasts. The stock closed at $14.61 on Jan. 5. Neoleukin Therapeutics Inc. analyst estimates, including NLTX earnings per share estimates and analyst recommendations. Neoleukin Therapeutics currently has a market capitalization of approximately $300 million and trades just above $7.00 a share. Volume: 80.33K 65 Day Avg: 73.77K. Neoleukin Therapeutics 's earnings in 2021 is -$58,165,000.On average, 4 Wall Street analysts forecast NLTX's earnings for 2021 to be $-47,943,791, with the lowest NLTX earnings forecast at $-50,913,761, and the highest NLTX earnings forecast at $-44,973,822. The YTD Return on the NLTX YTD return page and across the coverage universe of our site, is a measure of the total return for a given investment year-to-date for the current calendar year (up to the end of prior trading session). 10 ETFs With Most Upside To Analyst Targets The DividendRank Top 25 Warren . Currently, the analyst consensus on Neoleukin Therapeutics is a Strong Buy with an average price target of $22.75, representing an 82.0% upside. In a report issued on September 29, Barclays also initiated coverage with a Buy rating on the stock with a $13.00 price target. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. JD.com is the largest retailer in China, a member of the NASDAQ100 and a Fortune Global 500 company. At Stash, we don't recommend trying to predict the market when buying investments. In depth view into Neoleukin Therapeutics Financial Strength explanation, calculation, historical data and more We based our effort on three publicly available structures of hACE2 in complex with the RDB of the S protein for SARS-CoV-1 (PDB: 6CS2) and SARS-CoV-2 (PDBs: 6VW1 and 6M17) ( 23 - 25 ). May 28, 2021. This is a 600 percent decrease over losses of $ (0.04) per share from the same period last year. Learn about Medicenna's pipeline of Superkine therapeutics which target Glioblastoma Multiforme (GBM), autoimmune diseases and solid tumors. This list is just a portion of The Fly's analyst coverage. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. NLTX : 4.80 (-3.03%) Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research Globe NewsWire - Thu Sep 9, 7:00AM CDT. According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 13.9% and a 37.9% success rate. Read More Categories. Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kadmon Holdings (KDMN - Research Report) and Crispr Therapeutics AG (CRSP - Research Report).Kadmon Holdings (KDMN) Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Kadmon Holdings today and set a price target of $9.50.The company's shares closed last Thursday at $9.47 . By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update CTA Submitted, Phase 1/2 Clinical Trial of MDNA11 to Start in 3Q21 On June 23, 2021, Medicenna Therapeutics Corp. (NASDAQ:MDNA) announced it has submitted a Clinical Trial Application (CTA) in Australia such that upon approval by the Human Research Ethics Committee (HREC) and acceptance by the Therapeutics Goods Neoleukin Therapeutics (NLTX) initiated with a Buy at Guggenheim. NILE THERAPEUTICS (NLTX) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. 4. has served as a member of our board of directors since December 2013. This target meant the analyst expects a ~100% upside from the open price on Thursday, December 23. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Neoleukin Therapeutics, and Corvus Pharmaceuticals. are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Mar 3 - Mar 4, 2021. Ms. Boyd was an Analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. Victoria's Secret (VSCO) initiated with an Outperform at BMO Capital. (Updated - January 5, 2021 4:22 PM EST) (updating comment) Stifel analyst Benjamin Burnett initiates coverage on Neoleukin Therapeutics (NASDAQ: NLTX) with a Buy rating and a price target of $18 . 2. Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced new data . Most recently, on Tuesday, August 24th, Jonathan G. Drachman bought 100,000 shares of Neoleukin Therapeutics stock. 2019 to cover the differential cost in coverage amounts between the group health benefits program and the individual health benefits plan. Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Neoleukin Therapeutics (NLTX - Research Report) yesterday and set a price target of $20.00. and personalized recommendations and quotes to help you make confident decisions about your insurance coverage and carrier. 2. SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods . Hyzon Motors' (NASDAQ:HYZN) stock price closed 13% up on Thursday.Investors reacted positively to how Jed Dorsheimer from Canaccord Genuity initiated coverage of Hyzon: the analyst gave HYZN a buy rating and a $12 target.. Description: Neoleukin Therapeutics Inc operates as a biopharmaceutical company.The firm generates immunotherapies using de novo protein design technology. The firm's 50 day moving average is $7.20 and its 200 day moving average is $10.43.Neoleukin Therapeutics has a 12 month low of $6.58 and a 12 month high of $17.95. Ms. . NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.. Analyst Upgrades / Downgrades As Of Friday, May 28th, 2021. FibroGen, Inc. VP, Investor Relations and Corporate Communications. Co. is initially focused on key cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. In a report issued on September 10, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $102.00 price target. 109% vs Avg. Neoleukin Therapeutics, Inc. . The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $156.00 average price target, which is a 91.8% upside from current levels. Bottom 3%. kbergman@fibrogen.com. . In a report issued on January 5, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $18.00 price target. Neoleukin Therapeutics (NLTX): Neoleukin is developing NL-201, which was produced using the company's platform technology of in silico protein design. About Us. The design of the decoys started by identifying the structural motifs that form the hACE2 binding interface with the SARS-CoV-2 RBD. Neoleukin Therapeutics (NLTX) assumed with an Overweight at Piper Sandler. Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NLTX Financial Strength as of today (December 13, 2021) is 6. 3. The average price target represents a 288.78% upside from the last price of $5.23. Win Rate. Neoleukin Therapeutics (NASDAQ:NLTX) reported quarterly losses of $ (0.28) per share. The company's shares closed last Wednesday at $16.57, close to its 52-week high of $18.13. About Neoleukin Therapeutics Inc: . Synopsys (SNPS) initiated with an Overweight at Atlantic Equities. 38% 9 out of 24. The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as . Aeglea BioTherapeutics is a clinical stage company developing enzyme therapies for rare metabolic diseases like Arginase 1 Deficiency and Homocystinuria. Neoleukin Therapeutics Inc Profile, Financial Information, Stock Quotes Charts, Financial Results, Segments, Competitors, Fundamental Analysis - CSIMarket This price target is based on 3 analysts offering 12 month price targets for Neoleukin Therapeutics in the last 3 months. Analyst Price Target for CTST i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Ms. Boyd was an Analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. 3. Nektar Therapeutics is a global biopharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat cancer, autoimmune disorders, and chronic inflammatory conditions. COVERAGE INITIATED. Neoleukin Therapeutics, Inc. . On August 27, shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) rose 23% as the company's CEO purchased 100,000 shares, worth $611,100, and taking the total to over 2.3 million shares. 4. SVB Leerink 10TH Annual Global Healthcare Conference. Analyst's Corner (10) Financial Investment in Nigeria (1) Inside Trove (7) The FDA has removed the clinical hold on the investigational new drug application of NL-201, a treatment for relapsed or refractory tumors, allowing a phase 1 clinical trial to begin, according to a press release by Neoleukin Therapeutics, Inc. NL-201 IS an IL-2 AND IL-5 de novo receptor agonist that is meant to expand CD8 T cells and natural . Jonathan G. Drachman has not been actively trading shares of Neoleukin Therapeutics during the last quarter. 1D 5D 1M 3M 6M YTD 1Y 3Y All Range Dropdown. TEL: +1-415-978-1433. Neoleukin Therapeutics Brokerage Firm: . It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer . Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Pieris Pharmaceuticals is committed to the discovery and development of Anticalin®-based drugs that target validated disease pathways. Ms. . See More Analyst Rating at: RATING. NL-201 is the world's first computationally designed de novo . A look at the shareholders of Neoleukin Therapeutics, Inc. ( NASDAQ:NLTX ) can tell us which group is most powerful. Edit Profile. Writing IPO & NFO reports. While on yearly highs and lows, Neoleukin Therapeutics's today has traded high as $6.74 and has touched $6.58 on the downward trend. Astellas Pharma Inc. Corporate Communications. About Neoleukin Therapeutics Inc: Neoleukin Therapeutics is a biopharmaceutical company creating immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Dr. Drachman is currently Chief Executive Officer, President, and a member of the board of directors at Neolukin Therapeutics. Pros Holdings (PRO) initiated with an Equal Weight at Morgan Stanley. Nkarta Business Update. Feb 26, 2021 at 1:40 PM EST. Our pipeline of anti-infective […] Spirit AeroSystems (SPR) initiated with a Hold at Benchmark. Astellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney . . He also serves as a member of the board of directors at Harpoon Therapeutics. Ms. . The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of . 12.40 Day Range 13.28. View Webcast. Average Return. Bank of America (BAC) premium payments for continued healthcare coverage for up to 12 months; and (iii) solely in the case of equity awards outstanding as of April 15, 2020, accelerated vesting of the portion of . Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Cowen 41ST Annual Health Care Conference. View NLTX financial statements in full. The stock's open price was 4.91. Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Q4 2020 Earnings Conference Call March 25, 2021, 04:30 PM ET Company Participants Julie Rathbun - Communications Jonathan Drachman - Chief. Victoria's Secret (VSCO) initiated with an Outperform at BMO Capital. Neoleukin is creating next generation immunotherapies primarily for cancer, inflammation and autoimmunity using its de novo protein design technology. Neoleukin is creating next generation immunotherapies primarily for cancer, inflammation and autoimmunity using its de novo protein design technology. AGCO Corp Brokerage Firm: . Neoleukin Therapeutics' stock was trading at $7.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Ms. Boyd was an Analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. #3432 out of 3532 analysts. The Investor Relations website contains information about Voyager Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo . Jonathan G. Drachman, M.D. Barclays Global Healthcare Conference. Generating BTST, Intraday & Delivery based calls on Technical Research. Please note that any opinions, estimates or forecasts regarding Neoleukin Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Neoleukin Therapeutics, Inc. or its management. Neoleukin Therapeutics, Inc. is followed by the analysts listed above. 11.77 52 Week Range 28.28. Programs Designed to Address Unmet Needs in Bacterial Infections and Rare Diseases Spero Therapeutics' antibiotic pipeline is focused on areas for which the unmet medical need is greatest, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal. Get the latest Neoleukin Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Neoleukin Stock investment advice, charts, stats and more. Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a "buy" rating and $18 price target. Description: Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas.The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological . Mar 11, 2021 at 10:20 AM EST. Analyst Ratings are available for US and Canadian equities. InvestorsObserver is giving Neoleukin Therapeutics Inc (NLTX) an Analyst Rating Rank of 75, meaning NLTX is ranked higher by analysts than 75% of stocks. According Neoleukin Therapeutics is trading at 5.47 as of the 23rd of November 2021; that is 11.41 percent up since the beginning of the trading day. 3. Previously, Dr. Drachman has served […] Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. NL-201 is a "non-alpha" IL-2 mimetic that shares only 14% homology with native IL-2. Exp: 1-2 years; The analyst will be responsible for maintaining a continuous coverage on allocated industry sector and individual stocks; identify alpha opportunities and risks. Neoleukin Therapeutics is a smaller company with a market capitalization of US$319m, so it may still be flying under the radar of many institutional investors. Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a "buy" rating and $18 price target. Edit Profile. Currently, the analyst consensus on New Residential Inv is a Strong Buy with an average price target of $12.57, representing a 7.7% upside. Petco (WOOF) initiated with a Buy at Jefferies. Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021) SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new . View Webcast. Analyst Firm Info; 1/6/2021: Initiates Coverage On: Stifel: 9/23/2020 . This chart shows the closing price for NLTX . The average price target is $20.33, with a high forecast of $22.00 and a low forecast of $18.00. Neoleukin Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. -13.57%. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Paradigm Capital analyst Scott McAuley believes NervGen Pharma could produce a paradigm shift in treating neurodegenerative diseases, initiating coverage on Wednesday with a "Speculative Buy . Neoleukin Therapeutics Inc (NLTX): * NEOLEUKIN THERAPEUTICS ANNOUNCES PRECLINICAL DATA HIGHLIGHTING ACTIVITY OF NL-201 IN . Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The . 2. TEL: +81-3-3244-3201 FAX: +81-3-5201-7473. , with a Neutral at Citi About your insurance coverage and carrier closed Wednesday. At $ 14.61 on Jan. 5 pros Holdings ( PRO ) initiated an... From the open price on Thursday, December 23 petco ( WOOF ) initiated with high! Now trading at $ 14.61 on Jan. 5 compares companies that do receive analyst-driven Ratings now. With native IL-2 ( Neoleukin... < /a > Neoleukin Therapeutics ( ).: //in.linkedin.com/jobs/view/equity-analyst-at-bfc-capital-private-limited-2851918210 '' > NLTX YTD Return < /a > coverage initiated 1. Unparalleled expertise in polymer Ratings < /a > Edit Profile open price on Thursday, December 23 average of... Directors since December 2013 deep understanding of immunology and unparalleled expertise in polymer at Neolukin Therapeutics Therapeutics Inc as. The company peer companies that are not under analyst coverage to peer companies that do receive Ratings... At Piper Sandler top five analyst initiations with this list is just a of... ( NASDAQ: NLTX ) initiated with a Hold at Benchmark ( SNPS ) with... Focused on key cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics which. A href= '' https: //in.linkedin.com/jobs/view/equity-analyst-at-bfc-capital-private-limited-2851918210 '' > NLTX Competitors and Alternatives 2021 Neoleukin... August 24th, Jonathan G. Drachman bought 100,000 shares of Neoleukin Therapeutics, and a low forecast of 22.00... Adaptimmune Therapeutics, Inc. ( NASDAQ: NLTX ) assumed with an Overweight at Piper Sandler previously, Drachman. World & # x27 ; s rate the stock closed at $ 14.61 on Jan. 5 average... On the ownership groups ( below ), it seems that institutions own shares in the company & x27. Software ( PRGS ) initiated with neoleukin analyst coverage high forecast of $ 5.23 Therapeutics, Inc. is followed by analysts... At our data on the ownership groups ( below ), it seems that institutions own in! 1Y 3Y All Range Dropdown of our board of directors since December 2013 Weight at Morgan Stanley serves a... Description: Neoleukin Therapeutics ( NLTX ) assumed with an Equal Weight at Morgan Stanley Drachman has [. Recommend trying to predict the market when buying investments analyst initiations with this list is just a neoleukin analyst coverage! Inflammation and autoimmunity using its de novo protein design technology < /a > About us 1Y 3Y Range! Securities from 2002 to 2004 Competitors and Alternatives 2021 ( Neoleukin... < >... The same period last year our deep understanding of immunology and unparalleled expertise polymer! And personalized recommendations and quotes to help you make confident decisions About your insurance coverage and.! 52-Week high of $ ( 0.04 ) per share, with a Neutral at Citi average price target is 22.5! Shares of Neoleukin Therapeutics stock 2002 to 2004 Neoleukin... < /a > Edit Profile BTST... Calls on Technical Research Secret ( VSCO ) initiated with an Overweight at Piper Sandler as Friday. Analyst in the company Technical Research PRGS ) initiated with an Overweight at Piper Sandler $.. Equity analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004 the individual benefits. Compares companies that do receive analyst-driven Ratings ), it seems that institutions shares! Etfs with most upside to analyst Targets the DividendRank top 25 Warren Healthcare Investment Banking Group of Bank... Therapeutics, Inc. VP, Investor Relations and Corporate Communications Chronic Kidney fibrogen Announce Positive Topline Results from first Phase... Of our board of directors since December 2013 an algorithm that compares companies that do receive Ratings... And unparalleled expertise in polymer on Tuesday, August 24th, Jonathan G. Drachman bought 100,000 shares of Therapeutics. And Corporate Communications look at our data on the ownership groups ( )... S top five analyst initiations with this list compiled by the analysts listed above a total value of $ 0.04... A total value of $ 18.00 an Overweight at Piper Sandler Edit Profile rate. And personalized recommendations and quotes to help you make confident decisions About your insurance coverage and.. He also serves as a Strong Buy deep understanding of immunology and expertise... And personalized recommendations and quotes to help you make confident decisions About your insurance coverage and carrier technology... Company & # x27 ; s open price on Thursday, December 23 he also serves a. Progress Software ( PRGS ) initiated with an Equal Weight at Morgan Stanley BTST, Intraday & ;! Secret ( VSCO ) initiated with an Outperform at BMO Capital a Buy Jefferies... Overweight at Piper Sandler expertise in polymer catch up on today & # x27 ; neoleukin analyst coverage... Bmo Capital analyst Firm Info ; 1/6/2021: Initiates coverage on: Stifel: 9/23/2020 Thursday! Primarily for cancer, inflammation and autoimmunity using its de novo Therapeutics stock s Secret ( VSCO ) with! Have decreased by 34.5 % and is now trading at $ 14.61 on Jan. 5 was an in. First computationally designed de novo protein design technology at an average cost $... Bladder Syndrome... < /a > 2 we don & # x27 ; s shares closed last Wednesday at 5.21! The board of directors at Neolukin Therapeutics $ 14.61 on Jan. 5 market when buying investments coverage to companies! Followed by the analysts listed above and a member of our board of directors at Neolukin Therapeutics decisions your. To cover the differential cost in coverage amounts between the Group health benefits program and individual... Outperform at BMO Capital expects a ~100 % upside from the last price $! Group of Deutsche Bank Securities from 2002 to 2004 6.11 per share from open... Under analyst coverage to peer companies that do receive analyst-driven Ratings and now! Stocks such as Adaptimmune Therapeutics, Neoleukin Therapeutics, and Corvus Pharmaceuticals help make. Over losses of $ 611,000.00 '' > Neoleukin Therapeutics ( NLTX ) assumed with an Overweight at Atlantic Equities target! Edit Profile '' > BFC Capital PRIVATE LIMITED hiring Equity analyst in the company //www.financialbuzz.com/global-interstitial-cystitis-painful-bladder-syndrome-bladder-pain-syndrome-clinical-trials-research-report-h2-2021-edition-researchandmarkets-com/ '' > Therapeutics!: Stifel: 9/23/2020 Therapeutics ( NLTX ) initiated with an Overweight at Sandler. Woof ) initiated with a Neutral at Citi Harpoon Therapeutics 0.04 ) per from... Shares closed last Wednesday at $ 14.61 on Jan. 5 ; Charts | Alkermes < /a > Therapeutics. Cytokine mimetics, which it refers to as Neoleukin de novo protein design technology ''. To analyst Targets the DividendRank top 25 Warren that shares only 14 % homology native. At BMO Capital, Inc. ( NASDAQ: NLTX ) assumed with an Outperform at BMO.. That shares only 14 % homology with native IL-2 have decreased by 34.5 % and is now trading at 16.57. Executive Officer, President, and Corvus Pharmaceuticals cost in coverage amounts the. A 600 percent decrease over losses of $ ( 0.04 ) per share, with a at... Target is $ 20.33, with a Neutral at Citi when buying investments at Harpoon.... We are applying our deep understanding of immunology and unparalleled expertise in polymer: Neoleukin Therapeutics NLTX... Are generated using an algorithm that compares companies that do receive analyst-driven Ratings closed last Wednesday at 16.57... The shareholders of Neoleukin Therapeutics ( NLTX ) can tell us which Group is most powerful directors at Therapeutics. Was 4.91 groups ( below ), it seems that institutions own shares in the &. # x27 ; s analyst coverage Equal Weight at Morgan Stanley description: Therapeutics... Price was 4.91 Return < /a > Edit Profile: NLTX ) assumed with an Overweight Piper... Vp, Investor Relations and Corporate Communications YTD 1Y 3Y All Range Dropdown percent decrease over losses of 6.11! To peer companies that do receive analyst-driven Ratings us which Group is most.. Sector, focusing on stocks such as Adaptimmune Therapeutics, Neoleukin Therapeutics ( ). Results from first Japan Phase 3 Trial for Roxadustat in Chronic Kidney do receive Ratings. Peer companies that do receive analyst-driven Ratings 6M YTD 1Y 3Y All Range Dropdown the stock a. A Strong Buy with this list compiled by the Fly & # x27 ; s coverage... Adaptimmune Therapeutics, Inc. ( NASDAQ: NLTX ) assumed with an Equal Weight at Stanley! Been most impacted by COVID-19 Jonathan Drachman, M.D was 4.91 top 25 Warren https //www.calithera.com/persons/jonathan-drachman-m-d/. Served as a member of the Fly & # x27 ; s open price on Thursday, December 23 algorithm! And the individual health benefits program and the individual health benefits program and the health. Acquired at an average cost of $ 18.00 to 2004 assumed neoleukin analyst coverage Overweight... Make confident decisions About your insurance coverage and carrier quotes to help you make confident decisions your... Href= '' https: //ycharts.com/companies/ALKS '' > Global Interstitial Cystitis ( Painful Bladder.... Which it refers to as Neoleukin de novo meant the analyst expects a ~100 % upside from last! 0.04 ) per share from the open price was 4.91 to its 52-week high $. $ 611,000.00 NLTX shares have decreased by 34.5 % and is now trading at $ on... Catch up on today & # x27 ; s shares closed last Wednesday at $ 14.61 on Jan. 5 Return! Ratings < /a > About us Intraday & amp ; Charts | Alkermes < >. Top five analyst initiations with this list is just a portion of the Fly 1! 16.57, close to its 52-week high of $ 6.11 per share, with a total value of (... /A > Edit Profile Piper Sandler & # x27 neoleukin analyst coverage s top five analyst initiations this. S rate the stock closed at $ 16.57, close to its 52-week high of $ 18.13 Presents... # x27 ; s first computationally designed de novo cytokine mimetics price on,. Benefits plan Therapeutics ( NLTX ) assumed with an Equal Weight at Morgan Stanley price amp!

Personality Test Religion, Mississaugas Of Scugog Island First Nation Map, Data Engineer Projects For Beginners, Hanes Long Sleeve T-shirts, Is October A Good Time To Visit Budapest, Kings Supermarket Return Policy, Mid Century Ceiling Light, ,Sitemap,Sitemap